Clinical Study to Evaluate Efficacy of Cabergoline to Coasting in Reducing the Incidence of Ovarian Hyperstimulation Syndrome

Recruiting now · Phase 2

Conditions studied: Gynecologic Disease

In brief

Ovarian hyperstimulation syndrome (OHSS) is a serious iatrogenic complication of controlled ovarian stimulation of gonadotrophin-Stimulated ovarian cycles. It is theorized to manifest systemically as a result of vasoactive mediators like vascular endothelium growth factor (VEGF) being released from hyperstimulated ovaries. As a result, capillary permeability is increased which causes the extravasation of fluid from the intravascular compartment into the third space. The haemoconcentration which ensues results in complications such as hypercoagulability and reduced end organ perfusion.

Key facts

Study ID

NCT07043322

Run by

Tanta University

People needed

150

Starts

2025-06-30

Expected to finish

2026-11-20

Last updated by the study team

2026-03-13

Who can join

Age: 20 and older, up to 35. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Age between 18-38 years
• Body mass index (calculated as weight in kilograms divided by the square of height in meters) < 30 kg/m2.
• A long luteal protocol is used for ovarian stimulation.
• Day 2 FSH <10 mIU/L and E2< 50 pg/ml
• High risk of OHSS, defined as having more than 20 follicles >12 mm in diameter and/or E2 levels > 3000 pg/ml when the size of the leading follicle is > 15 mm

You may not qualify if…

• The presence of chronic medical diseases, including liver cell failure, renal failure, uncontrolled hypertension, uncontrolled diabetes mellitus, or class 3 or 4 function heart disease in the New York heart association classification.
• Allergy to Cabergoline.

Where it is running

• Mostafa Bahaa — Damietta, New Damietta, Egypt (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.